SEC Form 4 · accession 0001127602-18-029520

BIOCRYST PHARMACEUTICALS INC · BCRX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Senior Vice President and CFO

Period of report

Oct 2, 2018

Accepted (ET)

Oct 4, 2018 · 1:09 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000882796

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Oct 2, 2018	M	3,250	$3.78	A	140,633	D
Common Stock^F1,F2	Oct 2, 2018	S	3,250	$7.19	D	137,383	D
Common Stock^F1	Oct 2, 2018	M	5,528	$3.22	A	142,911	D
Common Stock^F1,F3	Oct 2, 2018	S	5,528	$7.27	D	137,383	D
Common Stock^F1	Oct 3, 2018	M	972	$3.22	A	138,355	D
Common Stock^F1,F4	Oct 3, 2018	S	972	$7.26	D	137,383	D
Common Stock^F1	Oct 3, 2018	M	100	$3.78	A	137,483	D
Common Stock^F1	Oct 3, 2018	S	100	$7.45	D	137,383	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Emp. Stock Option (Right to Buy)^F1	$3.78	Oct 2, 2018	M	3,250	D	Jul 1, 2012	Jul 1, 2021	Common Stock	3,250	52,555	D
Emp. Stock Option (Right to Buy)^F1	$3.22	Oct 2, 2018	M	5,528	D	May 23, 2017	May 23, 2026	Common Stock	5,528	123,899	D
Emp. Stock Option (Right to Buy)^F1	$3.22	Oct 3, 2018	M	972	D	May 23, 2017	May 23, 2026	Common Stock	972	122,927	D
Emp. Stock Option (Right to Buy)^F1	$3.78	Oct 3, 2018	M	100	D	Jul 1, 2012	Jul 1, 2021	Common Stock	100	52,455	D

F1The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018.
F2The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.10 to $7.32. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F3The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.25 to $7.32. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F4The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.25 to $7.26. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.